tert-butyl 4-[(7-chloro-3,4-dihydro-1,1-dioxido-3-oxo-2H-1,2,4-benzothiadiazin-2-yl)methyl]piperidine-1-carboxylate | 1373032-19-9

• 分子结构分类: 有机化合物 - 有机杂环化合物
• 英文名称: tert-butyl 4-[(7-chloro-3,4-dihydro-1,1-dioxido-3-oxo-2H-1,2,4-benzothiadiazin-2-yl)methyl]piperidine-1-carboxylate
• CAS: 1373032-19-9
• 化学式: C₁₈H₂₄ClN₃O₅S
• 分子量: 429.925
• InChiKey: BLIDWJNBMPEFBI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.52
• 重原子数：
  28.0
• 可旋转键数：
  2.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  96.02
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-[(7-chloro-3,4-dihydro-1,1-dioxido-3-oxo-2H-1,2,4-benzothiadiazin-2-yl)methyl]piperidine-1-carboxylate 在 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 为溶剂， 反应 1.67h， 生成 4-[(7-chloro-1,1,3-trioxo-4H-1lambda6,2,4-benzothiadiazin-2-yl)methyl]-N-cyclohexyl-N-cyclopropylpiperidine-1-carboxamide
  参考文献：
  名称：

  Synthesis and evaluation of piperidine urea derivatives as efficacious 11β-hydroxysteroid dehydrogenase type 1 inhibitors in diabetic ob/ob mice

  摘要：

  11 beta-Hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) has attracted considerable attention as a potential target for the treatment of diabetes and metabolic syndrome. Herein we report the design, synthesis and efficacy evaluation of novel amide and urea 11 beta-HSD1 inhibitors. Structure-activity relationship studies led to the identification of 10c, which was efficacious in a diabetic ob/ob mouse model and reduced fasting and non-fasting blood glucose levels after ip dosing. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.095
• 作为产物：
  描述：

  7-chloro-2,3-dihydro-3-oxo-4H-1,2,4-benzothiadiazine 、 1-Boc-4-溴甲基哌啶 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 12.5h， 以22%的产率得到tert-butyl 4-[(7-chloro-3,4-dihydro-1,1-dioxido-3-oxo-2H-1,2,4-benzothiadiazin-2-yl)methyl]piperidine-1-carboxylate
  参考文献：
  名称：

  Synthesis and evaluation of piperidine urea derivatives as efficacious 11β-hydroxysteroid dehydrogenase type 1 inhibitors in diabetic ob/ob mice

  摘要：

  11 beta-Hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) has attracted considerable attention as a potential target for the treatment of diabetes and metabolic syndrome. Herein we report the design, synthesis and efficacy evaluation of novel amide and urea 11 beta-HSD1 inhibitors. Structure-activity relationship studies led to the identification of 10c, which was efficacious in a diabetic ob/ob mouse model and reduced fasting and non-fasting blood glucose levels after ip dosing. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.02.095